CD8A and head and neck squamous cell carcinoma: Cetuximab alone, as an inhibitor of the epidermal growth factor receptor, has been demonstrated to boost antitumor immunity by enchaining CD8+ T-cell activation and dendritic cell maturation in HNSCC.24 25